p53 at the crossroads of MPN treatment

4Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).1 © 2014 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Plo, I. (2014, July 31). p53 at the crossroads of MPN treatment. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2014-06-579623

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free